Replies to post #437532 on Anavex Life Sciences Corp (AVXL)

[ExtremelyBullishZig]

Well...unfortunately...it is always used every quarter. Especially when Missling says there is no need for further dilution.

[Investor2014]

Well AF did point out the obvious issue with the AVATAR readout.

I suspect that even Adam Feuerstein doesn't want to get in the crosshairs of trying to kill a drug that helps kids.

In his update on ACADIA filing their NDA for Trofinetide below also that as opposed to Missling's statement, no NDA was filed from AVATAR.

AF can't spell Rett though, despite being a 'journalist'.

Assuming no fumbles and an unequivocally good EXCELLENCE readout, we will either hear nothing from AF or for once at least something neutral.

Also you will find late November that Anavex will have tapped the LPC ATM as they always do to keep the runway stable, which of course is something someone lurking for years on the $AVXL board will already know.

$ACAD said tonight that its marketing application for trofinetide in Rhett Syndrome has been submitted to the FDA. https://t.co/wzJt3M1h4Q

Which is a good reminder that $AVXL promise to do same has... not happened. Failed studies are tough to submit to the FDA.

— Adam Feuerstein ✡️ (@adamfeuerstein) July 18, 2022